eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Consumer Health

Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
Telephone: +44 (0)1276 687300
Fax: +44 (0)1276 687284
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1276 687290
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 20/06/2008
SPC Do-Do Chesteze


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Do-Do

Do-Do Chesteze


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Ephedrine hydrochloride 18.31mg

Theophylline 100.00mg

Caffeine 30.00mg

For excipients see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Tablet


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

To relieve bronchial cough, wheezing, breathlessness and other symptoms of asthmatic bronchitis, also to clear the chest of mucus following upper respiratory tract infection.


Go to top of the page
4.2 Posology and method of administration

Adults: One tablet. Do not take more than one tablet in 4 hours or more than 4 tablets in 24 hours.

Children:

over 12 years: One tablet. Do not exceed 3 tablets daily, with an interval of at least 4 hours between each tablet.

under 12 years: Not recommended unless advised by a doctor.

Under 2 years: Do not use.

Route of administration: For oral use.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the constituents. Prostatic hypertrophy, hyperthyroidism, hypertension, ischaemic heart disease and cardiac disease. Use in patients taking MAO inhibitors or within 14 days of stopping treatment.


Go to top of the page
4.4 Special warnings and precautions for use

Precaution should be used in patients with diabetes, glaucoma, liver disease, fever, epilepsy and breast feeding.

The product label includes the following warning:

WARNING: Do not exceed the stated dose. Asthmatics should consult their doctor before using this product.

Do not take with other cough and cold medicine.

Keep all medicines out of the reach of children.

If symptoms persist consult your doctor.

CONTAINS THEOPHYLLINE


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Caffeine, ephedrine hydrochloride and theophylline interact with several other drugs. The most important reactions are:

Ephedrine hydrochloride:

Monoamime oxidase inhibitors, guanethidine

Theophylline:

Frusemide,β-blockers (eg propranolol), isoprenaline, cimetidine, oral contraceptives, aminoglutethimide, carbamazepine, lithium, phenytoin, sulphinpyrazone, rifampicin, erythromycin, ciprofloxacin and other quinolone antibiotics. The handling of theophylline may be influenced by age, smoking, diet and disease including hepatic dysfunction, heart failure, pneumonia, active viral infections and severe (irreversible) airway obstruction.

There are conflicting reports concerning potentiation of theophylline by influenza vaccine and physicians should be aware that the interaction may occur.

The concomitant use of theophylline and fluvoxamine should usually be avoided. Where this is not possible, patients should have their theophylline dose halved and plasma theophylline should be monitored closely.

Plasma concentrations of theophylline can be reduced by concomitant use of the herbal remedy St. John's wort (Hypericum perforatum).

Xanthines can potentiate hypokalaemia resulting from β2 agonist therapy, steroids, diuretics and hypoxia. Particular caution is advised in severe asthma. It is recommended that serum potassium levels are monitored in such situations..

Caffeine:

Cimetidine, oral contraceptives, ciprofloxacin.


Go to top of the page
4.6 Pregnancy and lactation

Ephedrine hydrochloride:

There is some evidence linking in vitro exposure to sympathomimetics (including ephedrine) to minor malformations. Therefore it is advised that the product is not given in pregnancy. The product label includes the warning “If you are pregnant or are receiving medicines from your doctor, consult him before using Do-Do”.

Theophylline:

Animal studies have shown no hazard. There is no evidence of safety of theophylline-containing preparations in human pregnancy.

Caution should be used in patients who are breast feeding.


Go to top of the page
4.7 Effects on ability to drive and use machines

There is no evidence to suggest that the administration of Do-Do would interfere with a patient's ability to drive.


Go to top of the page
4.8 Undesirable effects

Ephedrine hydrochloride:

Anxiety, restlessness, tremor, tachycardia, arrhythmias, insomnia, dry mouth, cold extremities, difficulty in micturition.

Theophylline:

Tachycardia, palpitations, nausea, gastrointestinal disturbances, insomnia, arrhythmias and CNS stimulation.

Caffeine:

Insomnia, anxiety.


Go to top of the page
4.9 Overdose

The signs of overdose are: Vomiting, agitation, restlessness, dilated pupils and sinus tachycardia. In severe overdose the signs are: Arrhythmias, ventricular and supraventricular tachycardia, hematemesis may occur, hypochloremia and convulsions may occur, difficulty in micturition.

Treatment is symptomatic, including gastric lavage, supportive therapy, treatment of convulsions, sedation for restlessness and supportive treatment of hypokalaemia.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Ephedrine hydrochloride:

Sympathomimetic amine. Relaxes bronchial muscle.

Theophylline:

Relaxes smooth muscle and relieves bronchial spasm.

Caffeine:

CNS stimulating activity.


Go to top of the page
5.2 Pharmacokinetic properties

Ephedrine hydrochloride (in Do-Do):

Single dose mean AUC24

660 (+ 228) ng.h/ml

Single dose mean Cmax

96 (+ 14) ng/ml

Single dose median Tmax

1.0 h

Repeat dose mean AUC24/3

480 (+ 280) ng.h/ml

Repeat dose mean Cmax

95 (+ 21) ng/ml

Repeat dose median Tmax

1.0 h

Repeat dose mean KEL

0.215 (+ 0.020) h-1

Theophylline (in Do-Do):

Single dose mean AUC

33.09 (+ 12.69) μg.h/ml

Single dose mean Cmax

3.03 (+ 0.61) μg/ml

Single dose median Tmax

1.3 h

Single dose mean KEL

0.107 (+ 0.030) h-1

Repeat dose mean AUC24/3

31.3 (+ 9.7) μg.h/ml

Repeat dose mean Cmax

5.58 (+ 1.50) μg/ml

Repeat dose median Tmax

1.0 h

Repeat dose mean KEL

0.132 (+ 0.056) h-1

Caffeine:

After 100mg oral dose, peak plasma concentrations of 1.5 - 2μg/ml are obtained within 1 - 2 hours.


Go to top of the page
5.3 Preclinical safety data

No additional data.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Lactose

Maize starch

Starch 1500 (pre-gelatinised maize starch)

Colour brown 12663

Alginic acid H/FD

Magnesium stearate

Stearic acid

Purified Talc Special


Go to top of the page
6.2 Incompatibilities

None.


Go to top of the page
6.3 Shelf life

5 years


Go to top of the page
6.4 Special precautions for storage

Protect from heat and moisture.


Go to top of the page
6.5 Nature and contents of container

PVC form pack

Pack size: 9 tablets


Go to top of the page
6.6 Special precautions for disposal and other handling

Medicines should be kept out of the reach of children.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Novartis Consumer Health (UK) Ltd.

Trading as Novartis Consumer Health

Wimblehurst Road

Horsham

West Sussex

RH12 5AB


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00030/0097


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

1 February 1998


Go to top of the page
10. DATE OF REVISION OF THE TEXT

11 April 2008


Go to top of the page
Legal Category

P



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/20683/SPC/


Active Ingredients/Generics

 
   theophylline
   caffeine
   ephedrine hydrochloride